Research Study to Compare a New Medicine Fast-acting Insulin Aspart to Another Medicine Insulin Aspart in Chinese People With Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.

Also called NCT04588259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 331 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04588259
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04588259. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-09 (actual); primary completion 2022-07-05 (actual). Results posted on 2024-03-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Faster aspart
Intervention (Drug)
Insulin aspart
Intervention (Drug)
Insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04588259
Content hash
2bc0ba240a4cca66c62448a973d897fbce2d70f5e1ea4f00b909a9f9a2b0f833